Powered by Guardant Infinity smart liquid biopsy platform, advanced multiomic test evaluates genomic, epigenomic and RNA-based molecular data
Guardant Health, Inc. , a leading precision oncology company, announced the launch of Guardant360 Tissue, the first molecular profiling test for tumor tissue that incorporates comprehensive multiomics analysis—including DNA, RNA, AI-powered PD-L1 and exome-wide methylation data—to provide researchers and cancer care teams with a more comprehensive view of cancer.
Health Technology Insights: PwC Strategy and Releases Report at IVI RMA Congress on ART’s Role in Mitigating Economic Impact of Demographic Changes in the U.S.
Guardant360 Tissue establishes a new standard in tissue molecular profiling, enabling a much broader dimension of insights to provide biopharma and oncologists with an unprecedented view of each individual tumor.
Powered by the Guardant Infinity smart liquid biopsy platform, the advanced Guardant360 Tissue test enables insights beyond what can typically be found using tests that do not incorporate comprehensive analysis of epigenetics. These insights can apply to important classes of therapeutics, such as PARP-inhibitors and immunotherapies, as well as important new classes of therapies in late-stage development. The test also enables classification and subtyping of each individual tumor at a much higher resolution, potentially enabling a new era of precision oncology research and clinical applications.
Health Technology Insights: GE HealthCare to showcase advancements in diagnostic accuracy and breast care at SBI 2025 Breast Cancer Imaging Symposium
In addition, since Guardant360 Tissue is built on the smart liquid biopsy platform, it requires 92% less tissue surface area for analysis than the industry norm. In a real-world assessment, more than 50% of tumor tissue samples from patients failed to meet the surface area requirement – meaning those patients couldn’t qualify for testing. The Guardant360 Tissue test allows biopharmaceutical researchers and healthcare providers to successfully analyze tissue samples with 40% fewer slides and thus test more patients using less precious tissue.
“Guardant360 Tissue establishes a new standard in tissue molecular profiling, enabling a much broader dimension of insights to provide biopharma and oncologists with an unprecedented view of each individual tumor,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “And because it is built on our smart liquid biopsy platform, the test will leverage the countless multiomic applications that are being built around our Guardant360 liquid biopsy ecosystem. We believe this synergy will provide a new level of clinical actionability and improved patient outcomes across our entire product portfolio.”
For biopharmaceutical partners, the Guardant360 Tissue test offers differentiated molecular profiling by its extensive and unique genomic and epigenomic offering. The test analyzes 742 DNA genes and fusions in 367 RNA genes, with the ability to provide exome-wide analysis of the tumor methylome.
Health Technology Insights: Parabilis Medicines Reports Positive Proof-of-Mechanism Data for Groundbreaking ERG Degrader Program
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
